May. 6 at 7:24 PM
🚨
$GANX - Parkinson's drug GT-02287 just wrapped Phase 1b. Here's what the data shows:
21 patients enrolled. 19 completed 90 days. 84% of eligible patients voluntarily chose to continue into the 9-month extension. You don't stay in a trial if it's not working.
✅Extension ongoing until Q3 2026 → 16 patients. Results coming.
✅Safety, tolerability + biomarker signal in Parkinson's patients with or without GBA1 mutation.
✅First-in-human already confirmed GCase target engagement.
Phase 2 launch targeted Q3 2026.
4 analysts. All Strong Buy.
$7.50 price target.
The extension retention rate tells the story.
Communicated Disclaimer - DYOR too. https://chartingdaily.com/structural-health
Other biotech stocks running up today:
$PYXS $AVTX $ERNA